BioSpace News Archive

The global flexible sigmoidoscopy market was valued at USD 504.4 million in 2018 and is expected to reach USD 748.8 million by 2024, at a CAGR of 6.9% during the forecast period from 2019 to 2024 according to latest study from Emergen Research.

According to latest study from Emergen Research, the global drug discovery services market is expected to grow at a CAGR of 7.7% from 2016 to 2022 to reach USD 18.06 billion by 2022.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) (“Hemostemix” or the “Company”) is pleased to announce the appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board.

AltruBio Inc. announced that AltruBio President and CEO Dr. Judy Chou will speak on “The Next Wave of Targeted Therapies” at the Longwood Healthcare Leaders Fall Webconference on Wednesday, September 21, 2022.

Defence Therapeutics Inc., a Canadian biotech company actively working on accelerating scientific discoveries and products development against cancer, congratulates the US President Joe Biden for the executive order signed on Monday establishing the Biotechnology and Biomanufacturing initiative to ensure cutting-edge biotechnologies necessary to end cancer as we know it, and other innovations to be developed and manufactured in America.

Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the LSI Europe 2022 Emerging MedTech Summit in Hertfordshire, United Kingdom on September 21-24, 2022.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has made a founding, five-year gift to establish the University of Notre Dame’s Patient Advocacy Initiative in the College of Science.

Taglich Brothers, Inc. announces it has initiated coverage of BioSig Technologies, Inc.

Evofem Biosciences, Inc. announced another new insurance win that gives millions of additional women access to Phexxi® for the prevention of pregnancy.

Aditxt, Inc. announced the pricing of a public offering of 3,333,333 shares of its common stock, together with warrants to purchase up to 3,333,333 shares of its common stock at a combined offering price to the public of $6.00 per share and associated warrants.